Pharming Group N.V. (AMS:PHARM)

Pharming Group Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	189.56	145.31	54.94	61.74	207.34	191.92
Short-Term Investments	-	33.8	112.95	151.68	-	-
Cash & Short-Term Investments	189.56	179.1	167.89	213.42	207.34	191.92
Cash Growth	14.08%	6.68%	-21.33%	2.93%	8.03%	-6.45%
Accounts Receivable	74.83	41.77	41.53	35.41	20.96	18.08
Other Receivables	-	6.67	8.64	7.21	4.37	9.52
Receivables	74.83	48.44	50.17	42.62	25.33	27.59
Inventory	57.99	64.9	55.72	56.76	42.33	27.31
Prepaid Expenses	-	6.26	4.65	3.54	2.29	2.39
Restricted Cash	-	0.76	-	-	0.21	0.23
Other Current Assets	-	0	-	-	-	-
Total Current Assets	322.38	299.47	278.44	316.34	277.5	249.44
Property, Plant & Equipment	19.5	23.97	24.13	33.47	39.15	33.17
Long-Term Investments	8.59	8.65	4.23	10.4	9.73	8.65
Goodwill	-	3.32	-	-	-	-
Other Intangible Assets	125.67	132.22	61.04	71.27	74.87	83.57
Long-Term Deferred Tax Assets	19.05	31.02	30.54	29.76	22.97	21.22
Long-Term Deferred Charges	-	-	-	-	0.25	0.27
Other Long-Term Assets	1.45	1.32	1.6	1.62	1.33	1.01
Total Assets	496.64	499.96	399.99	462.85	425.8	397.32

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	90.07	8.55	10.1	16.02	8.75	7.6
Accrued Expenses	-	91.31	53.22	50.27	43.61	33.34
Current Portion of Long-Term Debt	5.58	5.34	4.25	1.82	1.77	1.88
Current Portion of Leases	3.48	3.37	2.95	3.62	3.47	2.42
Current Income Taxes Payable	-	6.04	3.28	6.23	2.1	1.51
Other Current Liabilities	0.82	1.19	-	-	-	0.03
Total Current Liabilities	99.95	115.79	73.8	77.97	59.7	46.77
Long-Term Debt	94.34	92.72	78.15	136.6	131.62	139.01
Long-Term Leases	11.1	14.35	26.97	29.51	29.84	18.46
Other Long-Term Liabilities	-	-	-	-	-	0.17
Total Liabilities	205.4	222.86	178.92	244.07	221.16	204.4

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	8.09	8.01	7.77	7.67	7.51	7.43
Additional Paid-In Capital	520.91	513.26	488.99	478.43	462.3	455.25
Retained Earnings	-255.28	-258	-287.92	-265.5	-265.17	-269.77
Comprehensive Income & Other	17.52	13.84	12.23	-1.82	-	-
Shareholders' Equity	291.24	277.1	221.06	218.78	204.64	192.92
Total Liabilities & Equity	496.64	499.96	399.99	462.85	425.8	397.32

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	114.51	115.78	112.31	171.55	166.69	161.76
Net Cash (Debt)	75.05	63.33	55.58	41.88	40.65	30.16
Net Cash Growth	112.92%	13.94%	32.72%	3.03%	34.76%	-30.18%
Net Cash Per Share	0.09	0.08	0.08	0.06	0.06	0.04
Filing Date Shares Outstanding	684.01	701.68	683.93	673.44	656.35	648.75
Total Common Shares Outstanding	684.01	701.68	680.31	671.07	656.35	648.75
Working Capital	222.43	183.68	204.64	238.37	217.8	202.67
Book Value Per Share	0.43	0.39	0.32	0.33	0.31	0.30
Tangible Book Value	165.57	141.56	160.02	147.51	129.77	109.35
Tangible Book Value Per Share	0.24	0.20	0.24	0.22	0.20	0.17
Land	-	-	-	-	-	0.03
Machinery	-	10.57	9.3	9.66	8.28	14.84
Construction In Progress	-	-	0.15	0.18	0.01	0.62
Leasehold Improvements	-	6.4	5.43	5.55	5.28	5.71

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error